Early initiation of antiretroviral therapy in patients with HIV/TB coinfection was associated with decreased mortality but increased risk for immune reconstitution inflammatory syndrome.
The STRIDE Study (ACTG 5221) was designed to evaluate the timing of antiretroviral therapy (ART) in patients with HIV/tuberculosis (TB) coinfection. In those with CD4 counts <50 cells/mm3, starting ART ≤2 weeks — as opposed to 8 to 12 weeks — after anti-TB therapy initiation was associated with a significantly lower rate of new AIDS-defining illness or death (NEJM JW AIDS Clin Care Oct 19 2011). However, early ART was also associated with development of immune reconstitution inflammatory syndrome (IRIS). Now, in a planned secondary analysis, investigators have examined the frequency, presentation, severity, and risk factors for TB IRIS.
TB IRIS developed in 61 (7.6%) of the 806 study participants, for an overall incidence of 9.0 per 100 pers…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)